Zentalis Pharmaceuticals Investor Presentation — November 2022

Document content

CORPORATE PRESENTATION

Zentalis Pharmaceuticals, Inc.(“we,” “us,” “our,” “Zentalis ”orthe “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward -looking statements

within the meaning ofthe U.S.Private Securities Litigation Reform Act of1995 .Allstatements contained inthis presentation that donot relate tomatters ofhistorical fact should beconsidered forward -looking

statements, including without limitation statements regarding potential forour product candidates tobefirst-in-class and/or best -in-class ;potential foraccelerated approval paths ;potential forour product

candidates tobedeveloped asmonotherapies and incombination ;potential forZN-c3toaddress large populations with significant unmet need ;ourdevelopment approach forourproduct candidates, including ZN-

c3;plans forand potential benefits ofdose optimization, and theanticipated timing ofupdates ondosing optimization ;timing ofpreclinical and clinical program updates ;thepotential unmet need inaparticular

indication and/or patient population ;potential forcombinations including our product candidates and thepotential benefits thereof ;the target profiles and potential benefits ofour product candidates and their

mechanisms ofaction, including asamonotherapy and/or incombination ;ourbelief that wehave strengthen ourclinical development plans, including forZN-c3;timing ofdiscontinuation activities forZN-c5and ZN-

c4;clinical and regulatory progress ofourproduct candidates, including theestimated timing ofIND-enabling studies, enrollment, initiation ofclinical trials and data announcements ;themarket opportunities forand

market potential ofourproduct candidates ;ouranticipated milestones ;and thepotential ofourcollaborations, aswell asstatements that include thewords “anticipate,” “design,” “estimate,” “expect,” “may,” “plan,”

“opportunity,” “potential,” “strategy,” “tocome,” “will” and similar statements ofafuture orforward -looking nature .These statements areneither promises nor guarantees, but involve known and unknown risks,

uncertainties and other important factors that may cause ouractual results, performance orachievements tobematerially different from any future results, performance orachievements expressed orimplied bythe

forward -looking statements, including, but notlimited to,thefollowing :theoutbreak ofthenovel coronavirus disease, COVID -19,has adversely impacted and may continue toadversely impact ourbusiness, including

ourpreclinical studies and clinical trials ;ourlimited operating history, which may make itdifficult toevaluate ourcurrent business and predict ourfuture success and viability ;wehave and expect tocontinue toincur

significant losses ;ourneed foradditional funding, which may notbeavailable ;oursubstantial dependence onthesuccess ofourlead product candidate ;failure toidentify additional product candidates and develop